Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case–control study
(2022)
Journal Article
Tan, P. S., Garriga, C., Clift, A., Liao, W., Patone, M., Coupland, C., …Hippisley-Cox, J. (2023). Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case–control study. Gut, 72(3), 512-521. https://doi.org/10.1136/gutjnl-2021-326522
Objective Prior studies identified clinical factors associated with increased risk of pancreatic ductal adenocarcinoma (PDAC). However, little is known regarding their time-varying nature, which could inform earlier diagnosis. This study assessed tem... Read More about Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case–control study.